The FDA clears an all-injection Skyrizi induction for Crohn's disease

The Food and Drug Administration has approved a new way to start Crohn's disease patients on risankizumab-rzaa, sold as Skyrizi: an entirely subcutaneous induction course that removes the intravenous infusions the drug has needed since it was first cleared for the condition [s1]. The change was recorded against supplement S-053 of the licence on 23 October 2026 [s2].

Until now, starting Skyrizi for Crohn's meant three intravenous infusions of 600 mg, given in a clinic at weeks 0, 4 and 8, before patients switched to at-home injections for maintenance [s1]. The revised label keeps that option but adds an alternative: 720 mg given by subcutaneous injection at weeks 0, 2, 4 and 8 [s1]. The dose is delivered as two 360 mg on-body injectors supplied together in a dedicated Crohn's induction pack [s1]. Maintenance is unchanged — 180 mg or 360 mg subcutaneously at week 12 and every eight weeks after [s1].

Why the route matters

For a chronic disease treated for years, how a drug is started is not a trivial detail. An intravenous induction ties the first two months of treatment to infusion appointments: a chair, a nurse, a cannula and the travel around them. An all-injection course lets suitable patients begin at home, which can mean faster starts and fewer clinic visits. It is the kind of label change that rarely makes headlines but reshapes the day-to-day experience of treatment.

Skyrizi is an interleukin-23 antagonist, one of a class of antibody drugs that block a signalling protein driving the gut inflammation of Crohn's disease. It is already approved across plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis [s1].

The evidence behind the change

The subcutaneous induction rests on a dedicated trial, CD-5 (NCT06063967), a 12-week, randomised, placebo-controlled study [s1]. Adults with moderately-to-severely active Crohn's disease — defined by a CDAI score of 220 to 450 and endoscopic activity — received either 720 mg of risankizumab subcutaneously at weeks 0, 2, 4 and 8, or placebo [s1].

On the two co-primary endpoints at week 12, the drug separated clearly from placebo. Clinical remission, meaning a CDAI below 150, was reached by 56% on risankizumab against 30% on placebo, a placebo-adjusted difference of 27% (95% CI 15 to 38, p < 0.001) [s1]. Endoscopic response — a visible healing of the gut lining at the camera examination — occurred in 43% versus 15%, a difference of 28% (95% CI 18 to 38, p < 0.001) [s1].

The agency also leaned on pharmacology to bridge the two routes. The label reports that total drug exposure after the subcutaneous induction was similar to that after the intravenous course, which is the technical ground for treating the new regimen as a genuine alternative rather than a weaker substitute [s1].

What to keep in view

A few caveats sit alongside the convenience. CD-5 tested the subcutaneous induction against placebo, not head-to-head against the intravenous course, so the case for route equivalence rests on the exposure comparison plus each regimen's own trial rather than a direct contest [s1]. The 720 mg induction is two injections per visit across four visits — more self-administered doses up front than the intravenous schedule's three clinic visits — which will suit some patients and not others.

The drug's safety profile is unchanged by the route. The label carries warnings on infection and on drug-induced liver injury during inflammatory-bowel-disease induction, with instructions to check liver enzymes and bilirubin before starting and through at least the first 12 weeks [s1]. The most common induction-phase adverse reactions in Crohn's trials were upper respiratory infections, headache and joint pain [s1].

What to watch

Whether clinicians and patients actually shift toward the injection route, and how payers treat the two options, will decide how much this matters in practice. The clinical result it is built on is solid for a 12-week induction; the open questions are longer-term and logistical, not about whether the drug works.

Red flags: anyone on an immune-modulating biologic who develops a persistent fever, signs of a serious infection, or symptoms of liver trouble such as yellowing skin, dark urine or right-sided abdominal pain should contact their care team promptly. This article describes an FDA regulatory action and is not medical advice. Decisions about Crohn's disease treatment are for patients and their treating gastroenterologists.